An end to the myth: There is no drug development pipeline

Science Translational Medicine

Volumn 5, Issue 171, 2013, Pages

  Baxter, Kristin ^a,b   Horn, Elizabeth ^a   Gal Edd, Neely ^a   Zonno, Kristi ^a,c   O'Leary, James ^a   Terry, Patrick F ^d   Terry, Sharon F ^a  

^a GENETIC ALLIANCE   (United States)

^b BOOZ ALLEN HAMILTON   (United States)

^c Myriad Genetic Laboratories   (United States)

^d PXE International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ADVOCACY ORGANIZATION; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; HEALTH CARE ORGANIZATION; HISTORY OF MEDICINE; HUMAN; MEDICAL DECISION MAKING; ORGANIZATIONAL DEVELOPMENT; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PUBLIC-PRIVATE PARTNERSHIP; PUBLICATION; REVIEW; STRATEGIC PLANNING; TRANSLATIONAL RESEARCH;

DISEASE; DRUG DISCOVERY; HUMANS; INFORMATION DISSEMINATION; MODELS, THEORETICAL; PATIENT ADVOCACY;

EID: 84874088207     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003505     Document Type: Review

References (23)

1. B. H. Munos, Pharmaceutical innovation gets a little help from new friends. Sci. Transl. Med. 5, 168ed1 (2013).
2. M. Kessel, The problems with today's pharmaceutical business - An outsider's view. Nat. Biotechnol. 29, 27-33 (2011).
3. B. Hughes, 2009 FDA drug approvals. Nat. Rev. Drug Discov. 9, 89-92 (2010).
4. C. B. Forrest, R. J. Bartek, Y. Rubinstein, S. C. Groft, The case for a global rare-diseases registry. Lancet 377, 1057-1059 (2011).
5. IOM Forum on Drug Discovery, Development, and Translation (www.iom.edu/Activities/Research/DrugForum.aspx);
6. Cancer Policy Forum (www.iom.edu/Activities/Disease/NCPF.aspx);
7. Roundtable on Translating Genomic-Based Research for Health (www.iom.edu/Activities/Research/GenomicBasedResearch.aspx);
8. Rare Disease Study (www.iom.edu/Activities/Research/ OrphanProductResearch.aspx).
9. W. A. Goolsby, L. Olsen, M. McGinnis, Clinical data as the basic staple of health learning: Creating and protecting a public good: Workshop summary, IOM Roundtable on Evidence-Based Medicine (Series), Institute of Medicine (2011); www.iom.edu/Reports/2011/Clinical-Data-as-the-Basic-Staple-for-Health-Learning. aspx.
10. A. Roses, "Personalized medicine: Elusive dream or imminent reality?": A commentary. Clin. Pharmacol. Ther. 81, 801-805 (2007).
11. M. A. Hamburg, F. S. Collins, The path to personalized medicine. N. Engl. J. Med. 363, 301-304 (2010).
12. S. F. Terry, C. D. Boyd, Researching the biology of PXE: Partnering in the process. Am. J. Med. Genet. 106, 177-184 (2001).
13. S. F. Terry, P. F. Terry, K. A. Rauen, J. Uitto, L. G. Bercovitch, Advocacy groups as research organizations: The PXE International example. Nat. Rev. Genet. 8, 157-164 (2007).
14. D. C. Landy, M. A. Brinich, M. E. Colten, E. J. Horn, S. F. Terry, R. R. Sharp, How disease advocacy organizations participate in clinical research: A survey of genetic organizations. Genet. Med. 14, 223-228 (2012).
15. S. F. Terry, E. J. Horn, J. Scott, P. F. Terry, Genetic Alliance Registry and BioBank: A novel disease advocacy-driven research solution. Per Med 8, 207-213 (2011).
16. S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, A. L. Schacht, How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
17. S. F. Terry, Accelerate medical breakthroughs by ending disease earmarks. Nat. Rev. Genet. 11, 310-311 (2010).
18. S. H. Friend, The need for precompetitive integrative bionetwork disease model building. Clin. Pharmacol. Ther. 87, 536-539 (2010).
19. S. H. Friend, Something in common. Sci. Transl. Med. 2, 40ed6 (2010).
20. A. M. Edwards, R. Isserlin, G. D. Bader, S. V. Frye, T. M. Willson, F. H. Yu, Too many roads not taken. Nature 470, 163-165 (2011).
21. A. M. Edwards, C. Bountra, D. J. Kerr, T. M. Willson, Open access chemical and clinical probes to support drug discovery. Nat. Chem. Biol. 5, 436-440 (2009).
22. Establishing precompetitive collaborations to stimulate genomics-driven product development - Workshop summary. IOM Roundtable on Translating Genomic-Based Research for Health (2010); www.iom.edu/Reports/2010/Establishing- Precompetitive-Collaborations-to-Stimulate-Genomics-Driven-Product-Development. aspx.
23. S. F. Terry, P. F. Terry, Power to the people: Participant ownership of clinical trial data. Sci. Transl. Med. 3, 69cm3 (2011).